scholarly journals Short-Term Effects of Atorvastatin in Normal Dogs and Dogs with Congestive Heart Failure Due to Myxomatous Mitral Valve Disease

2013 ◽  
Vol 27 (4) ◽  
pp. 985-989 ◽  
Author(s):  
S.M. Cunningham ◽  
J.E. Rush ◽  
L.M. Freeman
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
Short Term ◽  
Short Term Effects

scholarly journals Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease

2021 ◽  
Vol 8 ◽  
Author(s):  
Nakkawee Saengklub ◽  
Prapawadee Pirintr ◽  
Thanida Nampimoon ◽  
Anusak Kijtawornrat ◽  
Narongsak Chaiyabutr
Keyword(s):  
Heart Failure ◽  
Blood Pressure ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Left Ventricular ◽  
Valve Disease ◽  
Volume Index ◽  
Creatinine Ratio ◽  
Short Term ◽  
Short Term Effects

Background and Objective: Sacubitril/valsartan (SV) is an angiotensin receptor-neprilysin inhibitor that works by inhibiting the neprilysin enzyme as well as blocking angiotensin receptors. The benefits of using SV in congestive heart failure patients has been demonstrated in several clinical trials; however, limited data are available for dogs with heart failure. The aim of this study was to investigate the short-term effects of SV in comparison with ramipril in the standard therapy of symptomatic dogs suffering from myxomatous mitral valve disease (MMVD).Methods: In this prospective, randomized, single-blind study, 21 dogs with MMVD stage C were randomly assigned to received SV (20 mg/kg orally twice a day) or ramipril (0.125 mg/kg, orally once a day) in addition to pimobendan and furosemide. Echocardiography, electrocardiography, blood pressure, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and urinary aldosterone per creatinine ratio were obtained at baseline (D0) and at follow-up (4 weeks).Results: When comparing the percent change from baseline between groups, the left atrium to aortic root ratio (LA/Ao) and left ventricular internal diameter diastole normalized to body weight (LVIDDN) were significantly reduced in the SV group (P < 0.001 and P < 0.01, respectively). The end-diastolic volume index (EDVI), end-systolic volume index (ESVI), and stroke volume were lower in the SV group (P < 0.001, P < 0.05, and P < 0.01, respectively). No changes were observed between groups for NTproBNP, blood pressure, ECG parameters, and urinary aldosterone per creatinine ratio.Conclusion: The current study suggested that the short-term effects of SV can reverse myocardial remodeling, as inferred from several echocardiographic indices (i.e., the reduction in LA/Ao, LVIDDN, EDVI and ESVI) in dogs with MMVD stage C. These findings would support the use of SV in clinically symptomatic heart failure in dogs.

scholarly journals Blood lactate increases with the progression of mitral valve disease in dogs

2018 ◽  
Vol 38 (9) ◽  
pp. 1781-1786
Author(s):  
Jorge Cardoso Silva-Filho ◽  
Marlos G. Sousa ◽  
Evandro Zacché Pereira ◽  
Edna M.G. Ortiz ◽  
Rodrigo P. Franco ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Blood Lactate ◽  
Cardiac Remodeling ◽  
Mitral Valve Disease ◽  
Lactate Concentration ◽  
Tissue Perfusion ◽  
Valve Disease ◽  
Cross Sectional

ABSTRACT: In dogs with congestive heart failure, the upregulated sympathetic tone causes vasoconstriction that impairs peripheral blood supply, therefore causing the accumulation of lactate. In this prospective cross-sectional study with a longitudinal component, blood lactate was quantified in 10 healthy and 34 myxomatous mitral valve disease (MMVD) dogs to investigate its potential use as a diagnostic and prognostic biomarker. While there were no differences in lactate concentration between control animals and stages B1 (3.31±0.62mmol/L) and B2 (3.32±0.46mmol/L) dogs, significant differences were found between healthy (2.50±0.69mmol/L) and both C (3.99±0.47mmol/L) and D (6.97±1.23mmol/L) animals. When a cut-off of 3.35mmol/L was used, lactate was able to distinguish dogs with normal and remodeled hearts with a sensitivity of 78.2% and specificity of 63.6%. Also, significant correlations existed between lactate and indicators of cardiac remodeling. Finally, animals with blood lactate <3.5mmol/L carried a better prognosis when compared with dogs in which lactate was >5.0mmol/L. Our results suggest that the progression of MMVD results in accumulation of lactate within the bloodstream, which is likely attributable to the impaired peripheral tissue perfusion. In MMVD dogs, blood lactate may be used as a surrogate for cardiac remodeling, and an increased concentration is associated with a worse prognosis regarding the time to evolve into congestive heart failure.

Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: The PREDICT cohort study

2012 ◽  
Vol 14 (1) ◽  
pp. 193-202 ◽  
Author(s):  
Caryn A. Reynolds ◽  
Dorothy Cimino Brown ◽  
John E. Rush ◽  
Philip R. Fox ◽  
Thaibihn P. Nguyenba ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Cohort Study ◽  
Mitral Valve ◽  
Mitral Valve Disease ◽  
Valve Disease ◽  
First Onset

scholarly journals Depleted Myocardial Coenzyme Q10 in Cavalier King Charles Spaniels with Congestive Heart Failure Due to Myxomatous Mitral Valve Disease

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 161
Author(s):  
Liselotte B. Christiansen ◽  
Maria J. Reimann ◽  
Anne Marie V. Schou-Pedersen ◽  
Steen Larsen ◽  
Jens Lykkesfeldt ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mitral Valve ◽  
Coenzyme Q10 ◽  
Mitral Valve Disease ◽  
Defense Mechanisms ◽  
Citrate Synthase ◽  
Left Ventricular ◽  
Valve Disease ◽  
Tissue Samples

Congestive heart failure (CHF) has been associated with depleted myocardial coenzyme Q10 (Q10) concentrations in human patients. The aim of this study was to investigate associations between myocardial Q10 concentrations and myxomatous mitral valve disease (MMVD) severity in dogs. Furthermore, citrate synthase (CS) activity was analysed to determine if a reduction in myocardial Q10 was associated with mitochondrial depletion in the myocardium. Thirty Cavalier King Charles spaniels (CKCS) in MMVD stages B1 (n = 11), B2 (n = 5) and C (n = 14) according to the American College of Veterinary Internal Medicine (ACVIM) guidelines and 10 control (CON) dogs of other breeds were included. Myocardial Q10 concentration was analysed in left ventricular tissue samples using HPLC-ECD. CKCS with congestive heart failure (CHF; group C) had significantly reduced Q10 concentrations (median, 1.54 µg/mg; IQR, 1.36–1.94), compared to B1 (2.76 µg/mg; 2.10–4.81, p < 0.0018), B2 (3.85 µg/mg; 3.13–4.46, p < 0.0054) and CON dogs (2.8 µg/mg; 1.64–4.88, p < 0.0089). CS activity was comparable between disease groups. In conclusion, dogs with CHF due to MMVD had reduced myocardial Q10 concentrations. Studies evaluating antioxidant defense mechanisms as a therapeutic target for treatment of CHF in dogs are warranted.

Sign in / Sign up

Export Citation Format

Share Document